Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Melanoma
  Free Subscription

Articles published in
Br J Dermatol
    September 2025
  1. WHITEMAN DC
    BRAF testing for melanoma in England.
    Br J Dermatol. 2025 Sep 12:ljaf373. doi: 10.1093.
    >> Share

  2. HAFERKAMP S, Schilling B, Berking C, Drexler K, et al
    Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma - Results of a multicenter phase II study.
    Br J Dermatol. 2025 Sep 4:ljaf350. doi: 10.1093.
    >> Share

  3. MISTRY K, Jeffrey P, Levell NJ, Kennedy O, et al
    A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England 2016-21.
    Br J Dermatol. 2025 Sep 3:ljaf351. doi: 10.1093.
    >> Share

    July 2025
  4. NARDIN C, Cavalieri C, Lebbe C, Gerard E, et al
    Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).
    Br J Dermatol. 2025 Jul 14:ljaf268. doi: 10.1093.
    >> Share

  5. KARPONIS D, Mistry K, Stratigos G, Levell NJ, et al
    Can the effects of the COVID-19 pandemic provide insights into the impact of melanoma under-diagnosis and delayed care?
    Br J Dermatol. 2025 Jul 3:ljaf263. doi: 10.1093.
    >> Share

    June 2025
  6. BAI X, Flaherty KT
    The Rise of New Targets in Melanoma.
    Br J Dermatol. 2025 Jun 26:ljaf251. doi: 10.1093.
    >> Share

  7. ALANI O, Ahmed A, Haraldsdottir EL, Hoyt D, et al
    The Incidence and Impact of Melanoma Subtypes in Iceland 1955-2023.
    Br J Dermatol. 2025 Jun 23:ljaf248. doi: 10.1093.
    >> Share

  8. KAHLER S, Primiero C, Jayasinghe D, Mothershaw A, et al
    Unpredictable interdependence of invasive and in situ melanoma.
    Br J Dermatol. 2025 Jun 19:ljaf235. doi: 10.1093.
    >> Share

  9. SIA T, Li S, Zhong X, Park C, et al
    Acitretin chemoprevention in non-melanoma skin cancer patients with chronic hematopoietic disease: findings from three independent databases.
    Br J Dermatol. 2025 Jun 10:ljaf221. doi: 10.1093.
    >> Share

  10. LIU X, McBride JD
    Unmethylated PRAME DNA in Tissue and Plasma: A Promising Marker for Melanoma.
    Br J Dermatol. 2025 Jun 3:ljaf217. doi: 10.1093.
    >> Share

    May 2025
  11. WANG Y, Xu G, Xia H
    Targeting the MAPK Pathway for NRAS Mutant Melanoma: From Mechanism to Clinic.
    Br J Dermatol. 2025 May 9:ljaf178. doi: 10.1093.
    >> Share

  12. WHITEMAN DC
    Melanoma in England: incidence is up, mortality is down.
    Br J Dermatol. 2025 May 7:ljaf175. doi: 10.1093.
    >> Share

  13. ZHANG WW, Ke LF, Chen Y, Wu CY, et al
    Methylation-Based Test for Diagnosis of Benign and Malignant Melanocytoma.
    Br J Dermatol. 2025 May 2:ljaf169. doi: 10.1093.
    >> Share

    April 2025
  14. KARPONIS D, van Bodegraven B, Mistry K, Nikolaou V, et al
    Incidence and mortality of melanoma in situ and malignant melanoma in England between 2001 and 2020.
    Br J Dermatol. 2025 Apr 15:ljaf136. doi: 10.1093.
    >> Share

    March 2025
  15. KOCHI Y, Togawa Y, Yamazaki Y, Yamamoto Y, et al
    Anatomical distribution of acral lentiginous melanoma in the hand and nail among Japanese individuals.
    Br J Dermatol. 2025 Mar 4:ljaf070. doi: 10.1093.
    >> Share

    February 2025
  16. ACKERMANN DM, Bell KJL
    Setting the melanoma research agenda for all end-users: the need to include patient, clinician, and policy perspectives.
    Br J Dermatol. 2025 Feb 27:ljaf082. doi: 10.1093.
    >> Share

  17. NARDIN C, Vernerey D, Aubin F
    Ipilimumab + nivolumab combination or nivolumab monotherapy as first-line treatment in patients with metastatic melanoma: conclusions from a real-world French national cohort.
    Br J Dermatol. 2025 Feb 27:ljaf080. doi: 10.1093.
    >> Share

  18. MISTRY K, Srimudkul O, Patel M, Ragan J, et al
    Patient research priorities in melanoma: a national qualitative interview study.
    Br J Dermatol. 2025 Feb 27:ljaf048. doi: 10.1093.
    >> Share

  19. DELCOIGNE B, Lysell J, Askling J
    Incidence, stage and outcome of melanoma, keratinocyte and other cancers in individuals with vitiligo or alopecia: intraindividual or familial risks?
    Br J Dermatol. 2025 Feb 25:ljaf074. doi: 10.1093.
    >> Share

  20. LOPEZ S, Thakker S, Minkis K
    Beyond the Diagnosis: A Skin of Color Patient's Journey with Acral Lentiginous Melanoma.
    Br J Dermatol. 2025 Feb 6:ljaf047. doi: 10.1093.
    >> Share

    January 2025
  21. EGGERMONT CJ, Hollatz A, Wakkee M, Louwman M, et al
    Skin cancer risk in over 200.000 patients with haematologic malignancies in 30 years; a nationwide population-based study in the Netherlands.
    Br J Dermatol. 2025 Jan 24:ljaf027. doi: 10.1093.
    >> Share

  22. SMITH MJ, Peach H, Keohane S, Lear J, et al
    Melanoma: Assessment and Management summary of 2022 update of the NICE guidelines.
    Br J Dermatol. 2025 Jan 21:ljaf016. doi: 10.1093.
    >> Share

  23. ANDERSON ADG, Shirwac HF, Morgan H, Greenish H, et al
    Real-World Melanoma Miss-Rate In An NHS Hospital Dermatology Service. A Retrospective Study.
    Br J Dermatol. 2025 Jan 16:ljaf024. doi: 10.1093.
    >> Share

    December 2024
  24. PLACKE JM, Bottek J, Varaljai R, Shannan B, et al
    Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanoma.
    Br J Dermatol. 2024 Dec 31:ljae433. doi: 10.1093.
    >> Share

  25. WHITEMAN DC, Pandeya N, Olsen CM
    Differences in mean age at diagnosis of invasive melanoma for men and women, by anatomic site, thickness, and subtype.
    Br J Dermatol. 2024 Dec 17:ljae482. doi: 10.1093.
    >> Share

    November 2024
  26. KARINE B, Mortier L, Dereure O, Dalac S, et al
    The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab versus nivolumab in a real-world setting.
    Br J Dermatol. 2024 Nov 28:ljae470. doi: 10.1093.
    >> Share

  27. WOLBER AK, Jayasinghe D, Betz-Stablein B, Janda M, et al
    Incidence and patterns of newly developed pigmented lesions in adults at high risk for melanoma.
    Br J Dermatol. 2024 Nov 26:ljae467. doi: 10.1093.
    >> Share

  28. ZHENG DX, Jenkins RW
    Real-world data confirms limited efficacy of dual anti-PD-1 and CTLA-4 immune checkpoint blockade in acral lentiginous melanoma.
    Br J Dermatol. 2024 Nov 15:ljae445. doi: 10.1093.
    >> Share

  29. SANGERS TE, van Doorn R
    The usefulness of large language models for patient information on melanoma: challenges and opportunities.
    Br J Dermatol. 2024 Nov 1:ljae429. doi: 10.1093.
    >> Share

    October 2024
  30. WELLER RB, Gu J
    Ultraviolet radiation is not the major cause of melanoma mortality in the UK and sun exposure advice should be revised.
    Br J Dermatol. 2024 Oct 30:ljae426. doi: 10.1093.
    >> Share

  31. RAUWERDINK DJW, Hoogland Y, Schrader AMR, Potjer TP, et al
    Melanoma arising from pre-existing naevus in carriers of a germline CDKN2A pathogenic variant.
    Br J Dermatol. 2024 Oct 29:ljae417. doi: 10.1093.
    >> Share

  32. MCGILLIVRAY E, Ashouri K, Chatziioannou E, Gallegos JAO, et al
    Combined PD-1 and CTLA-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma.
    Br J Dermatol. 2024 Oct 23:ljae401. doi: 10.1093.
    >> Share

  33. KAMMINGA NC, Kievits JE, Plaisier PW, Burgers JS, et al
    Do Large Language Model Chatbots perform better than established patient information resources in answering patient questions? A comparative study on melanoma.
    Br J Dermatol. 2024 Oct 4:ljae377. doi: 10.1093.
    >> Share

  34. PANDEYA N, Olsen CM, Neale RE, Whiteman DC, et al
    Melanoma as a detection-dependent cancer: proxy measures of screening and surveillance associated with 3-year incidence of detection procedures for skin cancer in a national prospective study.
    Br J Dermatol. 2024 Oct 1:ljae372. doi: 10.1093.
    >> Share

    September 2024
  35. STEVENS HP, Pellacani G, Angus C, El-Jabbour JN, et al
    The use of Reflectance Confocal Microscopy to diagnose Malignant Melanoma and Lentigo Maligna in the United Kingdom: A Prospective Observational Trial at a Single Centre.
    Br J Dermatol. 2024 Sep 10:ljae354. doi: 10.1093.
    >> Share

  36. MAHUMUD RA
    The emerging burden of melanoma overdiagnosis in Australia: Who bears the cost-patients or the healthcare system?
    Br J Dermatol. 2024 Sep 9:ljae339. doi: 10.1093.
    >> Share

  37. POSADA V, Toland AE
    Role of albinism and pigment-related genes in amelanotic melanoma formation.
    Br J Dermatol. 2024 Sep 9:ljae353. doi: 10.1093.
    >> Share

  38. GELLER AC, Stratigos AJ
    Exploring sex and site- specific differences in melanoma.
    Br J Dermatol. 2024 Sep 4:ljae345. doi: 10.1093.
    >> Share

    August 2024
  39. YAMAZAKI E, Fujimura T, Takahashi-Watanabe M, Tada S, et al
    Decreased serum levels of IL-4 correlate with the efficacy of the PAI-1 inhibitor TM5614 in patients with malignant melanoma refractory to anti-PD-1 antibodies: post hoc study of TM5614-MM trial.
    Br J Dermatol. 2024 Aug 31:ljae343. doi: 10.1093.
    >> Share

  40. STURM RA, Smit DJ, Duffy DL, McLean C, et al
    Uncovering molecular mechanisms for amelanotic/hypopigmented primary cutaneous melanoma.
    Br J Dermatol. 2024 Aug 21:ljae336. doi: 10.1093.
    >> Share

    July 2024
  41. VAN DOORN R
    Supplemental vitamin D on trial: no evidence of benefit as an adjuvant treatment for melanoma.
    Br J Dermatol. 2024 Jul 23:ljae302. doi: 10.1093.
    >> Share

  42. LINDSAY D, Bell KJL, Olsen CM, Whiteman DC, et al
    Estimating the magnitude and healthcare costs of melanoma in situ and thin invasive melanoma overdiagnosis in Australia.
    Br J Dermatol. 2024 Jul 19:ljae296. doi: 10.1093.
    >> Share

  43. OLSEN CM, Pandeya N, Neale RE, Law MH, et al
    Phenotypic and genotypic risk factors for invasive melanoma by sex and body site.
    Br J Dermatol. 2024 Jul 19:ljae297. doi: 10.1093.
    >> Share

  44. LALLAS K, Spyridonos P, Kittler H, Tschandl P, et al
    Prediction of melanoma metastasis using dermatoscopy deep features. An international multicenter cohort study.
    Br J Dermatol. 2024 Jul 12:ljae281. doi: 10.1093.
    >> Share

  45. KLEEMANN J, Schilling B
    Multicenter phase II trial of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab in japanese advanced melanoma patients: Immune resistance remains one of the major efforts in melanoma research.
    Br J Dermatol. 2024 Jul 2:ljae279. doi: 10.1093.
    >> Share

    June 2024
  46. DE SMEDT J, Van Kelst S, Janssen L, Marasigan V, et al
    High dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind, placebo-controlled study (ViDMe trial).
    Br J Dermatol. 2024 Jun 24:ljae257. doi: 10.1093.
    >> Share

  47. MCMAHON M, Deacon DC
    Spatial sequencing reveals transcriptional variation between amelanotic and pigmented acral melanoma.
    Br J Dermatol. 2024 Jun 15:ljae253. doi: 10.1093.
    >> Share

  48. FUJIMURA T, Yoshino K, Kato H, Fukushima S, et al
    Phase II, multicenter study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-PD-1 antibody-refractory malignant melanoma: TM5614-MM trial.
    Br J Dermatol. 2024 Jun 4:ljae231. doi: 10.1093.
    >> Share

    May 2024
  49. CHOI ME, Choi EJ, Lee JH, Won CH, et al
    Spatial transcriptome analysis of amelanotic acral melanoma reveals distant molecular determinants compared to pigmented acral melanoma.
    Br J Dermatol. 2024 May 30:ljae224. doi: 10.1093.
    >> Share

  50. HANRAHAN GB, Tsibris HC
    Mutational Landscape and Tumor Mutational Burden in Adult Patients with Malignant Melanoma Arising From Congenital Nevi.
    Br J Dermatol. 2024 May 21:ljae214. doi: 10.1093.
    >> Share

  51. OLSEN CM
    Ecological evidence for melanoma overdiagnosis in Denmark.
    Br J Dermatol. 2024 May 16:ljae206. doi: 10.1093.
    >> Share

    April 2024
  52. NIELSEN JB, Kristiansen IS, Thapa S
    Increasing melanoma incidence with unchanged mortality: more sunshine, better treatment, increased diagnostic activity, overdiagnosis or lowered diagnostic threshold?
    Br J Dermatol. 2024 Apr 24:ljae175. doi: 10.1093.
    >> Share


  53. A novel strategy for the treatment of melanoma.
    Br J Dermatol. 2024;190:e51.
    >> Share


  54. Targeting malignant melanoma cells expressing the protein CD20 enhances BRAF-targeted treatment.
    Br J Dermatol. 2024;190:e58.
    >> Share

  55. JONES OT, Matin RN, Walter FM
    Using artificial intelligence-based technologies to support the diagnosis and early detection of melanoma in primary care.
    Br J Dermatol. 2024 Apr 9:ljae094. doi: 10.1093.
    >> Share

    March 2024
  56. TALTY R, Richmond R, Micevic G
    Melanoma TIL therapy commences era of cell-based immunotherapies.
    Br J Dermatol. 2024 Mar 22:ljae126. doi: 10.1093.
    >> Share


  57. AMBRA1 and loricrin as a test to identify low-risk early-stage melanoma.
    Br J Dermatol. 2024;190:e46.
    >> Share


  58. International trends in the incidence of cutaneous squamous cell carcinoma and melanoma.
    Br J Dermatol. 2024;190:e40.
    >> Share

    February 2024
  59. RIBERO S, Quaglino P, Roccuzzo G
    Unveiling cutaneous adverse events and prognosis in immunotherapy for melanoma and squamous cell carcinoma.
    Br J Dermatol. 2024 Feb 29:ljae092. doi: 10.1093.
    >> Share

  60. EGELER MD, Ryll B
    Survival is not enough: understanding the mental burden of cutaneous melanoma.
    Br J Dermatol. 2024 Feb 3:ljae050. doi: 10.1093.
    >> Share

    January 2024
  61. MUKHTAR AB, Morgan HJ, Gibbs A, Davies GE, et al
    Targeting CD20-expressing malignant melanoma cells augments BRAF inhibitor killing.
    Br J Dermatol. 2024 Jan 30:ljad502. doi: 10.1093.
    >> Share

  62. BERGAMASCHI D
    Improving cancer stem cells killing in malignant melanoma.
    Br J Dermatol. 2024 Jan 29:ljae035. doi: 10.1093.
    >> Share


  63. Risk factors for developing a new primary melanoma in people with a melanoma.
    Br J Dermatol. 2024;190:e15.
    >> Share


  64. Genes associated with nodular melanoma.
    Br J Dermatol. 2024;190:e18.
    >> Share

  65. PAPACHRISTOU P, Soderholm M, Pallon J, Taloyan M, et al
    Evaluation of an artificial intelligence-based decision support for detection of cutaneous melanoma in primary care - a prospective, real-life, clinical trial.
    Br J Dermatol. 2024 Jan 17:ljae021. doi: 10.1093.
    >> Share

  66. PENA-MARTIN J, Garcia-Ortega MB, Palacios-Ferrer JL, Diaz C, et al
    Identification of novel biomarkers for early diagnosis of malignant melanoma by untargeted LC-HRMS-based metabolomics: a pilot study.
    Br J Dermatol. 2024 Jan 12:ljae013. doi: 10.1093.
    >> Share

  67. COCCIMIGLIO M, Chiodo F, van Kooyk Y
    The sialic acid-Siglec immune checkpoint: an opportunity to enhance immune responses and therapy effectiveness in melanoma.
    Br J Dermatol. 2024 Jan 10:ljad517. doi: 10.1093.
    >> Share

  68. KUNGWENGWE G, Gowthorpe C, Ali SR, Warren H, et al
    Prevalence & Odds of Anxiety & Depression in Cutaneous Malignant Melanoma: A Proportional Meta-analysis & Regression.
    Br J Dermatol. 2024 Jan 10:ljae011. doi: 10.1093.
    >> Share

    December 2023

  69. Genetics and melanoma screening.
    Br J Dermatol. 2023;190:e4.
    >> Share

  70. EGGERMONT CJ, Eggermont AMM
    Shifting landscape in skin cancer incidence: the rising tide of cutaneous squamous cell carcinoma and potential implications for prevention.
    Br J Dermatol. 2023 Dec 14:ljad480. doi: 10.1093.
    >> Share

    November 2023
  71. MOHR C, Li Y, Navsaria LJ, Hinkston CL, et al
    Melanoma risk in skin of color patients with a history of a keratinocyte carcinoma.
    Br J Dermatol. 2023 Nov 30:ljad474. doi: 10.1093.
    >> Share

  72. EWEN T, Husain A, Stefanos N, Barrett P, et al
    Validation of Epidermal AMBRA1 and Loricrin (AMBLor) as a prognostic biomarker for non-ulcerated AJCC stage I/II cutaneous melanoma.
    Br J Dermatol. 2023 Nov 25:ljad459. doi: 10.1093.
    >> Share

  73. KAMMINGA NCW, Wakkee M, Swart I, Nijsten TEC, et al
    Determining the core content of a digital survivorship care plan for melanoma survivors: A multi-stakeholder Delphi-consensus study.
    Br J Dermatol. 2023 Nov 18:ljad450. doi: 10.1093.
    >> Share

  74. DESSINIOTI C, Stratigos AJ
    Decoding the nodular melanoma subtype- what about genetics?
    Br J Dermatol. 2023 Nov 17:ljad445. doi: 10.1093.
    >> Share


  75. Survival trends in people with melanoma in Sweden.
    Br J Dermatol. 2023;189:e108.
    >> Share

  76. SHIPMAN WD, Singh K, Cohen JM, Leventhal J, et al
    Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy: reply from the authors.
    Br J Dermatol. 2023 Nov 8:ljad342. doi: 10.1093.
    >> Share

  77. SMIT AK, Cust AE
    Unpacking factors contributing to melanoma overdiagnosis: does polygenic risk play a role?
    Br J Dermatol. 2023 Nov 6:ljad431. doi: 10.1093.
    >> Share

    October 2023
  78. OLSEN CM, Pandeya N, Ragaini BS, Neale RE, et al
    International patterns and trends in the incidence of melanoma and cutaneous squamous cell carcinoma, 1989-2020.
    Br J Dermatol. 2023 Oct 27:ljad425. doi: 10.1093.
    >> Share

  79. AUTIER P
    Melanoma incidence and COVID-19 lockdowns in the Netherlands.
    Br J Dermatol. 2023 Oct 4:ljad376. doi: 10.1093.
    >> Share

    September 2023
  80. STARK MS, Sturm RA, Pan Y, Smit DJ, et al
    Assessing the genetic risk of nodular melanoma using a candidate gene approach.
    Br J Dermatol. 2023 Sep 28:ljad365. doi: 10.1093.
    >> Share

  81. VAN DOORN R
    Multiple Primary Melanoma: Risk Factors Reviewed.
    Br J Dermatol. 2023 Sep 15:ljad343. doi: 10.1093.
    >> Share


  82. Features of very thin melanoma that predict lymph node involvement.
    Br J Dermatol. 2023;189:e74.
    >> Share

  83. GUERRERO-JUAREZ CF, Goyal PK, Amber KT
    Targeting IL-4/IL-13 in immune checkpoint inhibitor induced bullous pemphigoid: a cautionary note on the beneficial effect of Th2 in melanoma and immunotherapy.
    Br J Dermatol. 2023 Sep 13:ljad324. doi: 10.1093.
    >> Share

  84. PANDEYA N, Dusingize JC, Olsen CM, MacGregor S, et al
    Does genetic risk modify the effect of skin screening on melanoma detection rates?
    Br J Dermatol. 2023 Sep 8:ljad333. doi: 10.1093.
    >> Share

    August 2023

  85. Correction to: Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma.
    Br J Dermatol. 2023 Aug 24:ljad288. doi: 10.1093.
    >> Share


  86. Validation of a blood test for melanoma.
    Br J Dermatol. 2023;189:e65.
    >> Share

  87. CLAESON M
    Real-world data show improved melanoma survival in Sweden.
    Br J Dermatol. 2023 Aug 24:ljad309. doi: 10.1093.
    >> Share

  88. SMITH J, Cust AE, Lo SN
    Risk factors for subsequent primary melanoma for patients with previous melanoma: A systematic review and meta-analysis.
    Br J Dermatol. 2023 Aug 10:ljad275. doi: 10.1093.
    >> Share

    July 2023
  89. PAN CX, Kim DY, Lau CB, Lau WC, et al
    Comparative analysis of immune-related adverse events among patients with melanoma on immune checkpoint inhibitors: A retrospective cohort study.
    Br J Dermatol. 2023 Jul 28:ljad271. doi: 10.1093.
    >> Share

  90. VIKSTROM S, Mikiver R, Lapins J, Nielsen K, et al
    Increasing melanoma incidence and survival trend shifts with improved melanoma-specific survival between 1990 and 2020 in Sweden.
    Br J Dermatol. 2023 Jul 18:ljad244. doi: 10.1093.
    >> Share

  91. WAN J, Shin DB, Syed MN, Abuabara K, et al
    Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2023;189:53-61.
    >> Share

  92. GIUFFRIDA R, Zanin Poletto G, Guarneri F, Conforti C, et al
    Nevus count on the face for the identification of patients with higher risk of melanoma.
    Br J Dermatol. 2023 Jul 6:ljad216. doi: 10.1093.
    >> Share

  93. RIBERO S, Quaglino P, Roccuzzo G
    Predicting progression in very thin melanoma: the challenge of the next decade?
    Br J Dermatol. 2023 Jul 3:ljad218. doi: 10.1093.
    >> Share

    June 2023
  94. KAKISH H, Sun J, Zheng DX, Ali Ahmed F, et al
    Predictors of Sentinel Lymph Node Metastasis in Very Thin Invasive Melanomas.
    Br J Dermatol. 2023 Jun 8:ljad195. doi: 10.1093.
    >> Share

  95. VERGARA IA, Stark MS
    One Step Closer to Improving Melanoma Diagnosis and Prognosis with Liquid Biopsies.
    Br J Dermatol. 2023 Jun 3:ljad185. doi: 10.1093.
    >> Share

    May 2023
  96. MUTO Y, Kambayashi Y, Kato H, Fukushima S, et al
    Postoperative adjuvant therapy for120 melanoma patients, including acral and mucosal subtypes: A multicenter, observational study of two-year follow-up results.
    Br J Dermatol. 2023 May 27:ljad183. doi: 10.1093.
    >> Share


  97. Two melanoma genes (MITF and MC1R) interact to cause different risks.
    Br J Dermatol. 2023;188:e44.
    >> Share

  98. POGORZELSKA-DYRBUS J, Szepietowski JC
    Melanoma cells in optical super-high magnification dermoscopy.
    Br J Dermatol. 2023 May 22:ljad168. doi: 10.1093.
    >> Share

  99. VAN LAAR R, Latif B, King S, Love C, et al
    Validation of microRNA Liquid Biopsy for Diagnosis and Risk Stratification of Invasive Cutaneous Melanoma.
    Br J Dermatol. 2023 May 5:ljad137. doi: 10.1093.
    >> Share

    April 2023
  100. LALLAS A
    Which melanoma patients are at priority for monitoring to detect new primary melanoma?
    Br J Dermatol. 2023 Apr 17:ljad125. doi: 10.1093.
    >> Share

  101. IBRAHIM LS, Venables ZC, McPhail S, Levell NJ, et al
    Missing melanomas in England during the COVID-19 pandemic: 2,485 fewer melanoma diagnoses in 2020 than in 2019.
    Br J Dermatol. 2023 Apr 10:ljad117. doi: 10.1093.
    >> Share

  102. FUJISAWA Y, Namikawa K, Yoshino K, Kiniwa Y, et al
    Combined use of nivolumab and ipilimumab among Japanese melanoma patients: Multi-center, retrospective study of 111 cases.
    Br J Dermatol. 2023 Apr 5:ljad114. doi: 10.1093.
    >> Share

    March 2023

  103. Use of proton pump inhibitors in people taking BRAF/MEK inhibitors for metastatic melanoma.
    Br J Dermatol. 2023;188:e29.
    >> Share

  104. ASCOTT A, van Bodegraven B, Vernon S, Orteu CH, et al
    The geographical variation of melanoma, basal and squamous cell carcinoma in England.
    Br J Dermatol. 2023 Mar 30:ljad100. doi: 10.1093.
    >> Share

  105. ARACTINGI S, Oules B
    Correcting 'false' warnings with new tools? An illustrative example.
    Br J Dermatol. 2023;188:452.
    >> Share

  106. BRUNO W
    Joint contribution of MC1R and MITF alleles to melanoma risk in the age of polygenic risk scores.
    Br J Dermatol. 2023 Mar 28:ljad097. doi: 10.1093.
    >> Share

  107. NI Y, Watts CG, Scolyer RA, Madronio C, et al
    Risk of developing a second primary melanoma after a first primary melanoma in a population-based Australian cohort.
    Br J Dermatol. 2023 Mar 22:ljad076. doi: 10.1093.
    >> Share

  108. WALLINGFORD CK, Demeshko A, Krishnankutty Krishnakripa A, Smit DJ, et al
    MC1R 'r' allele does not increase melanoma risk in MITF E318K carriers.
    Br J Dermatol. 2023 Mar 5:ljad041. doi: 10.1093.
    >> Share

  109. OLSEN CM, Gordon LG, Carter SM, Whiteman DC, et al
    The ethical implications of opportunistic detection of melanoma in clinical care.
    Br J Dermatol. 2023 Mar 3:ljad055. doi: 10.1093.
    >> Share

  110. GHIASVAND R, Berge LAM, Andreassen BK, Green AC, et al
    Statin use and risk of cutaneous melanoma: A nationwide nested case-control study.
    Br J Dermatol. 2023 Mar 3:ljad057. doi: 10.1093.
    >> Share

    February 2023
  111. VAN BODEGRAVEN B, Vernon S, Eversfield C, Board R, et al
    "Get Data Out" Skin: national cancer registry incidence and survival rates for all registered skin tumour groups for 2013-2019 in England.
    Br J Dermatol. 2023 Feb 23:ljad033. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016